Structure Therapeutics Announces Participation in Upcoming Investor Conferences
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) will participate in two June 2026 healthcare investor conferences, featuring fireside chats and 1x1 meetings.
Events include the Jefferies Global Healthcare Conference on June 3 in New York and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9 in Miami, with live and archived webcasts available for 90 days.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – GPCR
On the day this news was published, GPCR declined 0.10%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $2.95B at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two upcoming healthcare conferences in June:
| 2026 Jefferies Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Wednesday, June 3 at 12:15 p.m. ET | |
| Location: | New York, NY | |
| Goldman Sachs 47th Annual Global Healthcare Conference | ||
| Format: | Fireside chat and 1x1 meetings | |
| Date/time: | Tuesday, June 9 at 10:00 a.m. ET | |
| Location: | Miami, FL | |
The live and archived webcasts will be accessible from the company’s website at https://ir.structuretx.com/events-presentations/events and replays will be available for 90 days.
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
